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Fc receptor-like 2 (FCRL2) is a novel marker
of low-risk CLL and reﬁnes prognostication
based on IGHV mutation status
Lauren K. Shea1, Kazuhito Honjo1, David T. Redden2, Edlue Tabengwa1, Ran Li1, Fu-Jun Li1, Mikhail Shakhmatov1,
Nicholas Chiorazzi3 and Randall S. Davis 1,4,5,6
Chronic lymphocytic leukemia (CLL) is the most pre-
valent leukemia in Western countries and is characterized
by a progressive accumulation of CD5+ monoclonal B
cells in the blood and bone marrow. The clinical course in
CLL is remarkably heterogeneous; the monoclonal
population may expand in a protracted fashion over many
years or increase rapidly, leading to bulky inﬁltration of
lymphoid organs, progressive cellular and humoral
immunodeﬁciency, autoimmunity, and cytopenias1,2.
Prognostication at the time of diagnosis has important
implications for patient care and has been an active area
of investigation over the past several decades. Various
means of risk stratiﬁcation have been developed and
validated, including clinical stage3,4, IGHV mutation sta-
tus5, cytogenetic abnormalities6, and expression of surface
proteins such as CD385,7 and CD49d8. Composite prog-
nostic indices, such as the German CLL Study Group
prognostic score and the CLL-IPI, have also been pro-
posed9,10. Despite an abundance of validated prognostic
indicators, decisions to initiate treatment are still based on
the presence of symptoms and/or cytopenias, and there is
no evidence yet that preemptive treatment based on
adverse prognostic factors improves overall survival (OS).
Therefore, the search for reliable and widely available
indicators that can be easily assayed at diagnosis and
integrated to reﬁne prognostication in CLL is ongoing.
Our own studies have focused on a family of Fc
receptor-like (FCRL1-5) molecules that have tyrosine-
based signaling potential and preferential expression by B
lymphocytes11. In healthy donor peripheral blood mono-
nuclear cell samples, the family member designated
FCRL2 identiﬁes subsets of CD19+CD27+memory B cells
and inhibits activation when co-ligated with the B-cell
receptor, but has not been found to bind Ig12. Interest-
ingly, in a series of 107 cryopreserved CLL samples,
FCRL2 emerged as a powerful prognostic indicator13.
FCRL2 expression was signiﬁcantly elevated on CLL
samples with mutated (M-CLL) as compared to unmu-
tated (U-CLL) IGHV sequences, showed 94.4% con-
cordance with IGHV mutation status, and was superior to
nine other factors (including IGHV status) analyzed in
predicting time to ﬁrst treatment (TFT). Extended follow-
up of our original 107-patient cohort showed that FCRL2
expression was predictive of OS as well as TFT (Fig. 1a).
As expected, IGHV mutation status was also predictive of
OS in our cohort. These encouraging results prompted us
to pursue optimization of assaying FCRL2 expression to
further its potential clinical use.
We ﬁrst set out to develop an FCRL2-speciﬁc mono-
clonal antibody (mAb) with superior reactivity and bind-
ing properties relative to our prior clone 7F213. After
institutional IACUC approval, BALB/c mice were hyper-
immunized with BW5147 mouse T cell line retroviral
transductants expressing FCRL2. Two separate fusions
were performed and an extensive analysis of 92 FCRL2-
reactive hybridoma clones was undertaken. This screen
led to the identiﬁcation of 3E11, a mouse IgG1κ subclone
that does not cross-react with the ﬁve other FCRL
molecules expressed by human lymphocytes (Fig. S1).
Blocking experiments indicated that 7F2 and 3E11 bind
distinct epitopes on FCRL2 (Fig. S2). To pursue further
characterization of the 3E11 clone, we directly conjugated
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it with phycoerythrin (PE) and stained PBMCs from CLL
donors to assess its reactivity. The direct conjugation of
3E11 with PE did not interfere with binding to CLL cells
(data not shown). Analysis of a M-CLL sample stained
indirectly with the previously described anti-FCRL2-mAb
7F2 (biotinylated and co-stained with SA-PE) versus
directly with 3E11-PE revealed stronger MFI reactivity for
the latter mAb (Fig. 1b). As expected, the staining
intensity of individual CLL samples for 3E11 and
7F2 showed a strong linear correlation (R2= 0.93)
(Fig. S3). We also compared the kinetics of the two mAbs
by examining their relative interactions with an FCRL2-Fc
chimeric protein by surface plasmon resonance (SPR).
3E11 had a higher overall nanomolar afﬁnity (approxi-
mately 2.3-fold) for the FCRL2 recombinant protein, as
well as a slower dissociation rate than 7F2 (Fig. 1c). In
addition, while 3E11 binding resembled a typical 1:1
Langmuir model, the 7F2 kinetic data indicated that its
epitope interaction is more complex and resembled a two-
step reaction. These data demonstrated that compared to
7F2, the 3E11 mAb exhibits higher surface staining
reactivity, 1:1 binding kinetics, and stronger overall afﬁ-
nity for FCRL2.
We next employed the PE-conjugated 3E11 mAb to
validate the prognostic signiﬁcance of FCRL2 by staining
samples from a new cohort of CLL patients. Out of 182
consecutive patients with CLL (as deﬁned by NCI cri-
teria)14 seen at our institution and consented with IRB
approval for banking over an approximately four-year
period (May 2014 through February 2018), we obtained
complete clinical and molecular data on 99 patients.
Characteristics of this new patient cohort are shown in
Table 1. We used maximum Youden Index values to
determine the optimal threshold cutoff value for percent
positivity of 3E11 based on the Receiver-Operating
Characteristic (ROC), in order to maximize correlation
with IGHV mutation status. This analysis identiﬁed 76.8%
as the optimal cut-off value. CLL samples with ≥76.8%
(see ﬁgure on previous page)
Fig. 1 a FCRL2 expression predicts overall survival (OS) in CLL patients. Extended clinical follow-up of a previously characterized cohort of CLL
patients (n= 107) assessed according to FCRL2 staining by ﬂow cytometry using the 7F2 mAb as previously described13. Kaplan-Meier plots for OS of
FCRL2-positive and negative patients were compared using the log-rank test, with Hazard Ratio (HR) and P-value displayed adjacent to the curves
(left). Similar analysis was performed to compare OS for patients with mutated (M-CLL) and unmutated (U-CLL) IGHV (right). All statistical analysis was
performed using SAS 9.1 (SAS Institute) and the RPART Package—R version 2.5.1 (The R Foundation for Statistical Computing). Graphs were
generated using GraphPad Prism 7.00 software. b 3E11 shows strong and selective staining reactivity for FCRL2 on CLL cells by ﬂow cytometry.
PBMCs were freshly isolated using Lymphocyte Separation Medium (Mediatech) at the time of study enrollment and analyzed immediately. Cells
were stained with anti-CD5-Briliant Violet (BV) 421 (clone UCHT2, BD Biosciences) and anti-CD19-allophycocyanin (APC) (clone HIB19, BD) to identify
the expanded CLL population. Cells were then analyzed by ﬂow cytometry after co-staining with the following anti-FCRL2 mAb clones: directly with
PE-conjugated 3E11 or indirectly with biotinylated 7F213 followed by streptavidin (SA)-PE (BD). After gating the lymphoid population according to
typical light scatter characteristics, a total of 1−5 × 105 events were acquired for analysis using an LSR ﬂow cytometer (BD) and analyzed with FlowJo
software (Tree Star). Histograms for FCRL2 are derived from the gated CD19+CD5+ CLL population (R1) and the subset frequency is noted. The
numbers in the histogram indicate the respective mean ﬂorescence intensity ratio (MFIR) as determined by dividing the MFI of the antigen-speciﬁc
ﬂuorochrome-conjugated mAb by the MFI of the irrelevant ﬂuorochrome-conjugated isotype-matched negative control mAb. c 3E11 shows stronger
binding kinetics with FCRL2 by surface plasmon resonance (SPR). SPR analysis was used to determine the kinetics of 7F2 (above) or 3E11 (below)
binding to an FCRL2-Fc recombinant protein generated as previously described15. SPR analysis was performed using a Biacore T100 instrument
upgraded to T200 speciﬁcations equipped with a CM5 sensor chip (GE Healthcare). Standard amine-coupling chemistry was used to immobilize
approximately 10,000–10,500 RU of a rat anti-mouse IgG1κ capture Ab (clone 187.1, Southern Biotech) onto the CM5 chip as recommended by the
manufacturer. For the subsequent capture step, the 3E11 and 7F2 mAbs were diluted to 2 µg/ml in HBS-EP+(0.01 M HEPES, pH 7.4, 0.15 M NaCl, 3 mM
EDTA, 0.05% vol/vol Surfactant P20 [GE]) running buffer and each mAb was injected over the 2nd or 4th surfaces for 60 s at a ﬂow rate of 10 μl/min at
25 °C. No mAb was injected over the 1st or 3rd channels, which served as reference surfaces. For measuring kinetics, two-fold serial dilutions of
FCRL2-Fc or Fc-only control proteins (in HBS-EP+) ranging from 100–3.125 nM, as well as blank buffer (for baseline subtraction), were sequentially
injected over the rat anti-mouse IgG1κ only (reference) or the captured 3E11 or 7F2 surfaces at 30 µl/min at 25 °C. Binding interactions were
monitored for 2 min association and 10min dissociation periods. Prior to curve ﬁtting, speciﬁc real-time binding sensorgrams were obtained by using
the standard double-referencing procedure, whereby the control surface and buffer blank injections are subtracted from the binding data. Biacore
T100 Curve Fit Evaluation Software Version 2.0.3 (GE) was used to determine binding kinetics. The binding curves from six concentrations of FCRL2-Fc
in the two-fold dilution series were then globally ﬁt into a typical 1:1 Langmuir binding model or into a two-step model with mass transport
limitation to determine the association (ka) and dissociation (kd) rate constants as well as the equilibrium dissociation constant (KD) of each
interaction (KD= kd/ka). Representative sensorgrams (colored lines) and kinetic model ﬁts (black dashed-lines) are shown. A control Fc-only protein
injected over the 7F2 and 3E11 surfaces did not show detectable binding to either mAb (not shown). For 7F2 (above), ka1= 1.85 × 10
5 (1/Ms), kd1=
1.79 × 10−2 (1/s), ka2= 3.93 × 10
−3 (1/Ms), kd2= 1.32 × 10
−3 (1/s), and KD= 2.43 × 10−8 (M). For 3E11 (below), ka= 5.54 × 104 (1/Ms), kd= 5.58 ×
10−4 (1/s), and KD= 1.06 × 10−8 (M). d FCRL2 staining with 3E11-PE is predictive of TFT in CLL patients. The 3E11 anti-FCRL2 mAb was used to
analyze samples from a new cohort of CLL patients (n= 99). Staining of freshly isolated PBMCs from CLL samples was performed as in (b). CLL
samples with ≥76.8% positivity for FCRL2 were designated FCRL2-positive and those with <76.8% positivity were designated FCRL2-negative as
described in the text. The Kaplan-Meier plot represents TFT for FCRL2-positive and negative patients and was generated and analyzed as in (a).
e, f FCRL2 staining reﬁnes prognostication in patients with low-risk CLL. Kaplan-Meier plots stratiﬁed by FCRL2 expression demonstrate the median
TFT for patients with M-CLL (e) and 13q deletion alone (f). Kaplan-Meier plots represent TFT for FCRL2-positive and negative patients and were
generated and analyzed as in Figure a
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reactivity were designated FCRL2-positive and those with
<76.8% reactivity were designated FCRL2-negative. Con-
sistent with its close association with IGHV mutation
status and our prior results obtained using the 7F2 mAb13,
FCRL2 was also a powerful predictor of TFT in the new
cohort, with median TFT for FCRL2-positive cases 36.4
years as compared to 5.26 years for FCRL2-negative cases
(HR 3.70, 95%CI 1.64 – 8.38, P < 0.0001, Fig. 1d). IGHV
status was also predictive of TFT, with median TFT for
M-CLL patients 36.4 years as compared to 2.76 years for
U-CLL patients (HR 6.28, 95%CI 2.61–15.1, P < 0.0001),
and both FCRL2 and IGHV status were superior pre-
dictors relative to CD38 (data not shown). Importantly,
among patients with M-CLL, FCRL2 could further reﬁne
prognostic capability. The combination of M-CLL and
positive FCRL2 surface expression conveyed a superior
prognosis. Median TFT was 36.4 years for FCRL2-positive
patients with M-CLL as compared to only 8.75 years for
FCRL2-negative patients with M-CLL (HR 3.31, 95%CI
0.465–23.6, P < 0.05, Fig. 1e). However, among patients
with U-CLL, FCRL2 did not improve prognostication of
TFT (data not shown). Similarly, for those with 13q
deletion alone, FCRL2 was able to stratify patients into
lower (median TFT 36.4 years) or higher (median TFT
5.13 years) risk groups (HR 5.53, 95%CI 0.685–44.6, P <
0.001, Fig. 1f).
We next performed a multivariable Cox proportional
hazard forward selection model including FCRL2, CD38,
IGHVmutation status, and cytogenetics (trisomy 12q, 13q
deletion, normal, 11q deletion, and 17p deletion). The
factors that emerged as the best predictors of TFT were
IGHV status and trisomy 12q. Likely due to its co-linearity
with IGHV, FCRL2 expression did not enhance prognostic
power when added to this model. However, when
IGHV status was excluded, FCRL2 expression and 17p
deletion emerged as the most powerful prognostic factors
(Table S1).
Though not superior to IGHV status in predicting TFT
in our patient cohort, FCRL2 expression was able to
further reﬁne and extend prognostication in M-CLL
patients with an already favorable prognosis. This is cer-
tainly important to individual patients, who may suffer
from signiﬁcant emotional distress upon being diagnosed
with a malignancy that is largely incurable, and then being
informed that observation until progression is the stan-
dard of care for asymptomatic individuals. A positive
prognostic marker such as FCRL2, readily testable by ﬂow
cytometry, may provide reassurance to patients and help
clinicians determine frequency of follow-up, though this
should be evaluated in clinical trials. In addition, we are
hopeful that investigation of the functional signiﬁcance of
FCRL2 expression levels in normal and malignant B cells
may provide further insight into the biology of CLL
There are several caveats to our data that should be
acknowledged. First, conﬁrmation of these results should be
pursued with an independent validation cohort of CLL
samples. The retrospective nature of this study, with some
patients diagnosed more than thirty years prior to data
analysis, made obtaining complete data from the time of
diagnosis challenging and thus prevented calculation of
composite prognostic indices such as the CLL IPI10.
Table 1 Clinical characteristics of CLL samples
Parameter All patients M-CLL U-CLL
No. of patients (%) 99 61 (61.6) 38 (38.4)
Sex, no. (%)
Male 53 (53.5) 28 (45.9) 25 (65.8)
Female 46 (46.5) 33 (54.1) 13 (34.2)
Age at diagnosis, y
Median 62 59 64
Range 40–84 40–84 40–80
Rai stage, no (%)
0 78 (78.8) 55 (90.2) 23 (60.5)
I-II 16 (16.2) 5 (8.2) 11 (28.9)
III-IV 5 (5.1) 1 (1.6) 4 (10.5)
Time to treatment
Median time to ﬁrst treatment, y 2.8 5.7 2.3
No. treated (%) 31 (31.3) 12 (19.7) 19 (50)
No. censored (%) 68 (68.7) 49 (80.3) 19 (50)
Cytogenetics
17p deletion, no. (%) 8 (8.1) 2 (3.3) 6 (15.8)
11q deletion, no. (%) 7 (7.1) 0(0) 7 (18.4)
13q deletion, no. (%) 50 (50.5) 44 (72.1) 6 (15.8)
12q trisomy, no. (%) 15 (15.2) 3 (4.9) 12 (31.6)
Normal, no. (%) 19 (19.2) 12 (19.7) 7 (18.4)
FCRL2 expression
Positive, no. (%) 61 (61.6) 52 (85.2) 9 (23.7)
Negative, no. (%) 38 (38.4) 9 (14.8) 29 (76.3)
CD38 expression
Positive, no. (%) 13 (13.1) 1 (1.6) 12 (31.6)
Negative, no. (%) 86 (86.9) 60 (98.4) 26 (68.4)
Samples were stained for FCRL2 expression as described in Fig. 1b. Median time
from diagnosis to sample collection and ﬂow cytometry was 4.29 years (range
0–34.2 years). CD38 surface measurements were determined with anti-CD38-PE
(clone HB-7, BD) according to published criteria5,7. A cutoff value of >30% was
used to determine a positive result. FISH for trisomy 12q, 13q deletion, 11q
deletion, and 17p deletion was performed according to standard methodology
by the UAB Department of Genetics. Cytogenetic proﬁles were categorized
according to the original hierarchy as described6. IGHV mutation status for CLL
samples was either determined in-house according to established methods as
previously described13 or performed by the Mayo Clinic Laboratories (Rochester,
MN). FISH and IGHV sequencing were determined at the time of diagnosis for
the majority of cases
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Furthermore, many of our patients underwent ﬁrst treat-
ment prior to the development of the molecular targeted
agents that are now transforming the treatment landscape
in CLL, and further study will be needed to examine the
role of FCRL2 in prognostication (and possibly prediction of
response) as CLL therapy evolves. Nevertheless, the fact
that FCRL2 was able to reﬁne prognostication of patients
with an already excellent prognosis (M-CLL, deletion 13q
positive) indicates a need for further prospective studies of
this readily assayable marker in both prognostication and
prediction of response.
In summary, we have shown that FCRL2 is a powerful
predictor of both TFT and OS in CLL and have validated
the prognostic signiﬁcance of FCRL2 in a new cohort of
patients. We have developed a novel PE-conjugated mAb
to FCRL2 that produces robust and speciﬁc staining of
clinical samples, with implications for reﬁning and
extending prognostication of low-risk disease. We are
hopeful that these ﬁndings will enhance both research and
clinical care in CLL.
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